Key Highlights

  • 37.6% is how far Candel Therapeutics (NASDAQ:CADL) trades below its USD 14.00 52-week high, at USD 8.73 on October 16, 2026 (own arithmetic on published market data). The 14-day RSI is 28.8 and the weekly decline is 9.9%.
  • 36.6% is the gap between Oruka Therapeutics (NASDAQ:ORKA) at USD 73.24 and its USD 115.52 high (own arithmetic). The RSI is 29.6, and the price sits 1.0% above the USD 72.50 offering price of April 28, 2026.
  • 29.3% is the gap between BridgeBio Pharma (NASDAQ:BBIO) at USD 66.07 and its USD 93.42 high (own arithmetic). Its 50-day average of USD 72.94 sits 0.193% below the 200-day average, a death cross, and the table published no RSI.
  • 26% is the gap between Travere Therapeutics (NASDAQ:TVTX) at USD 50.95 and its USD 68.73 high (own arithmetic). The RSI is 28.9, Filspari sales rose 96% in the second quarter, and chief executive Eric Dube announced on September 21, 2026 he will step down.

Candel Therapeutics (NASDAQ:CADL)

The market is weighing a binary filing against a financing overhang. Candel plans a Biologics License Application in the fourth quarter of 2026 for aglatimagene besadenovec in localized, intermediate to high-risk prostate cancer, citing a 39% improvement in disease-free survival against placebo. No company-specific catalyst for the decline was identified in the filings and releases reviewed through October 16, 2026; Zacks Research cut its rating to strong sell on October 14. What separates it from the other three is cash relative to size: USD 201.6 million at June 30, 2026 equals 30.2% of the USD 668 million market capitalization (own arithmetic). Second quarter operating costs of USD 26.7 million imply 22.7 months of runway (own arithmetic), consistent with the company estimate of the first quarter of 2028. Launch costs would shorten it, and raising capital after a filing dilutes holders, as the December 2024 offering at USD 6.00 did. The price is 4.4% below the 200-day average of USD 9.32 (own arithmetic). So what: a single-asset company converts a regulatory step into a financing event. Third quarter results are estimated for November 12, 2026.

Travere Therapeutics (NASDAQ:TVTX)

The question is whether a launch can survive a leadership handover. Travere reported second quarter Filspari net sales of USD 141.1 million, up 96% from USD 71.9 million, with total revenue of USD 169.6 million and a net loss of USD 34.8 million, per the August 4, 2026 release. Bradley Campbell, a former Amicus Therapeutics chief executive, is named successor, with a December 1 start per published market data. What separates it from the other three is that the business is growing fastest while the price fell least. Annualizing second quarter revenue gives a price to sales multiple of 7.1 (own arithmetic), and cash of USD 489.2 million equals 10.2% of market capitalization. The one-week change is only negative 2.09%, so the RSI of 28.9 reflects an earlier decline, and no negative company disclosure was found. Method-of-use patents extend protection to 2037. Risks are concentration in one drug and payer pressure. So what: the ASN Kidney Week presentations from October 21 to 25, 2026 and estimated results on October 29 are the next catalysts.

Oruka Therapeutics (NASDAQ:ORKA)

Strong data and a strong balance sheet have not held the price. Oruka reported on September 23, 2026 that 71.4% of patients reached PASI 100, clear skin, at Week 28 of the EVERLAST-A trial of ORKA-001, up from 63.5% at Week 16, yet shares fell 5% that morning. An analyst at Clear Street said the update met its base case, so the data confirmed expectations rather than beat them. What separates it from the other three is the offering reference: the April 28 raise sold 9.66 million shares at USD 72.50 for USD 700.4 million gross, and the stock trades 1.0% above that price (own arithmetic). Cash and marketable securities of USD 1.1 billion equal 22.7% of market capitalization (own arithmetic), and the first-half net loss of USD 73.0 million annualizes to USD 146 million, a 7.5-year runway before Phase 3 costs. The offering price is a reference level, not a guaranteed floor. So what: Week 16 data from the 187-subject EVERLAST-B trial in the fourth quarter can reprice the stock in either direction.

BridgeBio Pharma (NASDAQ:BBIO)

BridgeBio is the revenue leader of the four and the only one with a chart signal that lags rather than leads. The 50-day average of USD 72.94 is USD 0.14 below the 200-day average of USD 73.08 (own arithmetic), and the price is 9.6% below the 200-day. Attruby net product revenue was USD 222.4 million in the second quarter against USD 71.5 million a year earlier, per management commentary on the August 10, 2026 report. What separates it from the other three is dated regulatory risk: the FDA decision for BBP-418 is due November 27, 2026 under priority review, with infigratinib on February 4, 2027. A USD 1 billion preferred equity led by Sixth Street closed on July 1, 2026, lifting pro forma liquidity to USD 1,720.2 million, or 13.3% of the USD 12.92 billion market capitalization (own arithmetic). Short interest is 11.73% of float with 5.85 days to cover, per published market data. Pressures include the February 2026 revocation of a European tafamidis patent and generic risk. So what: the report is estimated for October 28, 2026.

Where Things Stand

Candel (NASDAQ:CADL) trades furthest below its high at 37.6%, followed by Oruka at 36.6%, BridgeBio at 29.3% and Travere at 26% (own arithmetic). Furthest from the high does not mean cheapest: the ranking by cash as a share of market capitalization is Candel at 30.2%, Oruka at 22.7%, BridgeBio at 13.3% and Travere at 10.2%. Travere (NASDAQ:TVTX) pairs the smallest drawdown with the fastest revenue growth. Oruka (NASDAQ:ORKA) faces a fourth quarter data readout, and BridgeBio faces a dated FDA decision on November 27, 2026. RSI is not a forecast, and each catalyst can move shares in either direction.